Alzamend Neuro Inc banner

Alzamend Neuro Inc
NASDAQ:ALZN

Watchlist Manager
Alzamend Neuro Inc Logo
Alzamend Neuro Inc
NASDAQ:ALZN
Watchlist
Price: 1.65 USD -7.3% Market Closed
Market Cap: $6.3m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Alzamend Neuro Inc
NASDAQ:ALZN
6.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
409.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
198.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
193.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
72.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.1B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Alzamend Neuro Inc
Glance View

Market Cap
6.3m USD
Industry
Biotechnology

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2021-06-15. The firm's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.

ALZN Intrinsic Value
1.04 USD
Overvaluation 37%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top